Alliance Global Partners analyst James Molloy lowered the firm’s price target on Can-Fite BioPharma (CANF) to $4.50 from $12 and keeps a Buy rating on the shares following the Q4 report. The company announced multiple clinical and developmental milestones outlined for its lead oral A3 adenosine receptor agonist candidates, Piclidenoson and Namodenoson, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CANF: